RYTM Latest Press Releases

-- November 3, 2026 --

Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update Globe Newswire 7:00 AM

-- November 2, 2026 --

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement Globe Newswire 9:59 PM

-- October 21, 2026 --

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 Globe Newswire 8:00 AM

-- October 13, 2026 --

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity Globe Newswire 7:30 PM

-- September 28, 2026 --

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm PRNewswire 9:10 AM

-- September 22, 2026 --

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity Globe Newswire 8:00 AM

-- September 10, 2026 --

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting Globe Newswire 8:00 AM

-- August 24, 2026 --

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan Globe Newswire 8:00 AM

-- August 17, 2026 --

Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer Globe Newswire 8:00 AM

-- August 11, 2026 --

Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment Globe Newswire 8:00 AM

-- August 4, 2026 --

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences Globe Newswire 4:01 PM

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Globe Newswire 7:01 AM

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity Globe Newswire 6:55 AM

-- July 21, 2026 --

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm PRNewswire 5:10 PM

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 Globe Newswire 8:00 AM

-- July 16, 2026 --

Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm Globe Newswire 9:16 PM

-- July 8, 2026 --

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity Globe Newswire 5:07 PM

-- June 15, 2026 --

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026 Globe Newswire 4:01 PM

-- June 13, 2026 --

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Globe Newswire 8:01 AM

-- June 12, 2026 --

Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome Globe Newswire 4:01 PM

Market Data Delayed 15 Minutes